Storm Floods Northern Philippine Regions, Including Capital, Disrupting Schools, Work and Travel 

Youths wade in a storm surge along Manila Bay amid heavy rains brought by Tropical Storm Yagi in Manila on September 2, 2024. (AFP)
Youths wade in a storm surge along Manila Bay amid heavy rains brought by Tropical Storm Yagi in Manila on September 2, 2024. (AFP)
TT

Storm Floods Northern Philippine Regions, Including Capital, Disrupting Schools, Work and Travel 

Youths wade in a storm surge along Manila Bay amid heavy rains brought by Tropical Storm Yagi in Manila on September 2, 2024. (AFP)
Youths wade in a storm surge along Manila Bay amid heavy rains brought by Tropical Storm Yagi in Manila on September 2, 2024. (AFP)

A storm unleashed pounding rains that flooded many northern Philippine areas overnight into Monday, prompting authorities to suspend classes and government work in the capital region and warn thousands of residents to prepare to evacuate from flood-prone villages along a key river.

Tropical Storm Yagi was blowing 115 kilometers (71 miles) northeast of Infanta town in Quezon province, southeast of Manila, on Monday with sustained winds of up to 75 kilometers (47 miles) per hour and gusts of up to 90 kph (56 mph), according to the weather bureau.

The storm, locally called Enteng, was moving northwestward at 15 kph (9 mph) near the eastern coast of the main northern region of Luzon, where the weather bureau warned of possible flash floods and landslides in mountainous provinces.

Two residents died amid the stormy weather in Naga city in eastern Camarines Sur province, where floodwaters swamped several communities, police said. Authorities were verifying if the deaths, including one caused by electrocution, were weather-related.

Storm warnings were raised in a large swath of Luzon, the country’s most populous region, including in metropolitan Manila, where schools at all levels and most government work were suspended due to the stormy weather.

Along the crowded banks of Marikina River in the eastern fringes of the capital, a siren was sounded in the morning to warn thousands of residents to brace for evacuation in case the river water continues to rise and overflows due to heavy rains.

In Northern Samar province, coast guard personnel used rubber boats and rope to evacuate 40 villagers on Sunday in two villages that were engulfed in waist- to chest-high floods, the coast guard said.

Sea travel was temporarily halted in several ports affected by the storm, stranding about 2,200 ferry passengers and cargo workers, and several dozen domestic flights were suspended due to the stormy weather.

Downpours have also caused water to rise to near-spilling level in Ipo dam in Bulacan province, north of Manila, prompting authorities to schedule a release of a minimal amount of water later Monday that they say would not endanger villages downstream.

About 20 typhoons and storms batter the Philippines each year. The archipelago lies in the “Pacific Ring of Fire,” a region along most of the Pacific Ocean rim where many volcanic eruptions and earthquakes occur, making the Southeast Asian nation one of the world’s most disaster-prone.

In 2013, Typhoon Haiyan, one of the strongest recorded tropical cyclones in the world, left more than 7,300 people dead or missing, flattened entire villages, swept ships inland and displaced more than 5 million people in the central Philippines.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”